Back to results
US 2026/0207757 A1Published application
Insulin-like growth factor-chemotherapeutic conjugate for treating myelodysplastic syndrome
AssigneeIGF Oncology, LLC
InventorsHugh McTavish, Arkadiusz Z. Dudek
Life of this patent
Estimating the term…
Abstract
Provided are methods of treating myelodysplastic syndrome (MDS), oligoblastic acute myelogenous leukemia (O-AML), or chronic myelomonocytic leukemia (CMML) using 765IGF-MTX and other IGF-receptor-targeted agents, and formulations for delivering 765IGF-MTX and other IGF-receptor-targeted agents to patients. Also provided are pharmaceutical compositions for use in treating MDS, O-AML, and CMML.
Claims12
1-23. (canceled)
A pharmaceutical composition that is a solution for infusion comprising:
- (a) an agent consisting of an IGF-1R ligand covalently conjugated to methotrexate, wherein the IGF-1R ligand is insulin-like growth factor 1 (IGF-1) or a variant thereof or insulin;
- dissolved in (b) 100 ml to 1 liter of 5% to 10% (w/v) dextrose in water, wherein the solution does not comprise more than 5 mM NaCl or more than 2 mM phosphate;
- wherein the solution is in an infusion bag and has a volume of 100 ml to 1 liter.
(canceled)
27-29. (canceled)
A device comprising:
- (a) an infusion bag capable of holding a maximum volume of 100 ml to 2 liters, filled with
- (b) a solution of 5% or 10% (w/v) dextrose and dissolved in the solution (c) an agent consisting of an IGF-1R ligand covalently conjugated to methotrexate, wherein the IGF-1R ligand is insulin-like growth factor 1 (IGF-1) or a variant thereof or insulin, the solution having a volume of 100 ml to 1 liter.
Dependencies are inferred from the claim text.